Myeloproliferative disease : nature.com subject feeds
Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis
RBC distribution width predicts thrombosis risk in polycythemia vera
Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Paradigm shift: combination BET and JAK inhibition in myelofibrosis
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party
Myelofibrosis: let’s go high!
Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001–2018
Germline POT1 variants can predispose to myeloid and lymphoid neoplasms
Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms
Long-term follow-up of recovered MPN patients with COVID-19
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation
Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis
Mutations and thrombosis in essential thrombocythemia
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera
A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
Feed Fetched by RSS Dog.